Cipher Pharmaceuticals (TSE:CPH) has released an update.
Cipher Pharmaceuticals reports that its partner Moberg Pharma AB has observed lower than expected clinical cure rates in a subset of patients for the MOB-015 nail fungus treatment study. Despite this setback, Cipher’s Canadian marketing rights remain unaffected as future payments are contingent on meeting specific milestones. The company emphasizes its focus on the recent Natroba business acquisition and its growth potential.
For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.
